Zetasizer Helix combines dynamic light scattering and Raman spectroscopy for advanced protein structure analysis

Zetasizer Helix combines dynamic light scattering and Raman spectroscopy for advanced protein structure analysis.

Raman spectroscopy delivers information on protein unfolding by monitoring the variations in molecular vibrations that result from changes in secondary and tertiary protein structure. The combination of dynamic light scattering with Raman spectroscopy characterizes a wealth of chemical, structural, and physical parameters of biotherapeutic proteins under formulation conditions - at high concentrations up to 100 mg/ml and using a wide range of buffers and excipients. Parameters measured include: secondary and tertiary protein structure; melting temperature; onset temperature of aggregation; and transition enthalpy values; as well as aggregation propensity and protein solubility.

The Zetasizer Helix is the latest commercialized product to emerge from Malvern''s Bioscience Development Initiative (BDI), a collaborative research program dedicated to providing solutions to the evolving needs of the biopharmaceutical industry. A key priority for the industry is obtaining a greater understanding and control over the formulation process, a need exacerbated by the increasing adoption of QbD. By allowing users to fully scope protein behavior within a formulation the Zetasizer Helix provides insight at the molecular level as to which variables trigger, for example, oligomerization and aggregation, supporting a QbD approach.

Find out more about how the Zetasizer Helix can help with protein characterization and the application of QbD within biopharmaceutical development at www.malvern.com/zshelix.

More information

Details

Malvern WR14 1XZ, UK

Malvern Instruments

Associated Trend items

Structure-based drug design: Selective WEE1 inhibitors

Despite many tremendous advances in cancer research over the last few decades, new treatments that further improve clinical outcomes and quality of life for patients are still highly sought after.

One class of small molecules that lead to many treatments now providing standard of care for cancer patients are kinase inhibitors. This target class contains over 500 members, many of which are undrugged. Protein kinase inhibitors are anticipated to deliver many more therapies to treat cancer and other diseases, such as fibrosis and rheumatoid arthritis. Small molecule...

More information

Advanced solid-state analysis capabilities on the bench

Live webinar 16 June 2022

Control of the solid form of a lead drug candidate through scale-up to clinic and commercial manufacture is essential for multiple reasons, including safety, efficacy and also IP. X-ray diffraction (XRD) is the gold standard technique for the assessment of a compound’s solid form and stability. Benchtop XRD systems enable greater access to this key technology, but in com...

More information

Ask an Expert! Hints and tips for customizing your thin film analysis using XRD

Whether you have questions about samples or sample prep, setting up an experiment, or performing analysis, feel free to submit them so that we can deliver the information you require.

There’s always more to learn, whether it’s setting up your measurements for quick batch processing, gaining confidence in the quality of your results, or presenting your data in the best format. For this webinar, we’ll assume you’ve watched the previous one on the same topic. Don't worry if you missed it or can't remember it – you can watch it back here. Don’t forget ...

More information

Compare

Remove all

Compare up to 10 products